Discover
AGEN
Agenus Inc.
3.41
2 x 2.40
2 x 3.91
bid
ask
+
0.35
11.44%
2 @ 04:00 PM
3.40 -0.01 (0.29%)
| Ytd | 8.60% | |
| 1y | -29.55% |
3.06
day range
3.42
2.71
52 week range
7.34
| Open | 3.06 | Prev Close | 3.06 | Low | 3.06 | High | 3.42 | Mkt Cap | 142.00M |
| Vol | 659.40K | Avg Vol | 942.68K | EPS | 2.05 | P/E | 1.66 | Forward P/E | -0.28 |
| Beta | 1.39 | Short Ratio | 4.16 | Inst. Own | 37.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 3.42 | 200-d Avg | 3.67 | 1yr Est | 8.00 |
AGEN News
gurufocus.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha
benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab I
Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus
businesswire.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio